Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel
Authors:
- Alan D. MichelsonAMAlan D. Michelson
- Stephen D. WiviottSWStephen D. Wiviott
- Dietmar TrenkDTDietmar Trenk
- Franz-Josef NeumannFNFranz-Josef Neumann
- Debra L. MillerDMDebra L. Miller
- Joseph A. JakubowskiJJJoseph A. Jakubowski
- Timothy M. CostiganTCTimothy M. Costigan
- Carolyn H. McCabeCMCarolyn H. McCabe
- Elliott M. AntmanEAElliott M. Antman
- Eugene BraunwaldEBEugene Braunwald
- 1 January 2011
- journal article
- research article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 106 (08) , 219-226
Abstract
Summary: It was the objective of this study to determine whether the intrinsic platelet response to adenosine diphosphate (ADP) before thienopyridine exposure contributes to residual platelet reactivity to ADP despite high level P2Y12 blockade by prasugrel (60 mg loading dose [LD]), 10 mg daily maintenance dose [MD]) or high-dose clopidogrel (600 mg LD, 150 mg daily MD). High residual platelet function during clopidogrel therapy is associated with poor clinical outcomes. It remains unknown whether the relationship between platelet reactivity prior to treatment with clopidogrel (300 mg LD, 75 mg daily MD) and residual on-treatment platelet reactivity is maintained after more potent P2Y12 inhibition. PRINCIPLE-TIMI 44 was a randomised, double-blind, twophase crossover study of prasugrel compared with high-dose clopidogrel in 201 patients undergoing cardiac catheterisation for planned percutaneous coronary intervention. ADP-stimulated platelet-monocyte aggregates, platelet surface P-selectin and platelet aggregation were measured pre-treatment, during LD (6 h and 18–24 h) and MD (15 d). Correlations of pre-treatment to on-treatment values were determined by Spearman rank order. Prasugrel resulted in greater platelet inhibition than high-dose clopidogrel for each measure. However, for both drugs, pre-treatment reactivity to ADP predicted 6 h, 18–24 h and 15 day reactivity to ADP (correlations 0.24–0.62 for platelet-monocyte aggregates and P-selectin). In conclusion, a patient's intrinsic platelet response to ADP before exposure to thienopyridines contributes to residual platelet reactivity to ADP despite high level P2Y12 blockade with high-dose clopidogrel or even higher level P2Y12 blockade with prasugrel. Patients who are hyper-responsive to ADP pre-treatment are more likely to be hyper-responsive to ADP on-treatment, which may be relevant to therapeutic strategies.Keywords
Funding Information
- Daiichi Sankyo Company Limited
This publication has 28 references indexed in Scilit:
- Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonistsNature Genetics, 2010
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel TherapyJAMA, 2009
- A functional genomics approach reveals novel quantitative trait loci associated with platelet signaling pathwaysBlood, 2009
- Personalized medicine for clopidogrel resistance?Nature Reviews Cardiology, 2009
- Methods for the Measurement of Platelet FunctionThe American Journal of Cardiology, 2009
- Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care AssayCirculation, 2009
- Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery diseaseThrombosis and Haemostasis, 2008
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent PlacementJACC, 2006
- Clopidogrel for Coronary StentingCirculation, 2003